ReviewCureus2025
Wearable Devices and AI-Driven Remote Monitoring in Cardiovascular Medicine: A Narrative Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Wearable Devices in Cardiovascular Care: A Narrative Review of the Transition Toward Predictive, Preventive, Personalized, and Participatory Medicine.Healthcare (Basel, Switzerland) · 2026Review
- Echocardiographic Phenomapping in HFpEF: From Imaging Biomarkers to Precision Cardiovascular Medicine.Echocardiography (Mount Kisco, N.Y.) · 2026Review
- Retrieval-Augmented Large Language Model Counseling for Continuous Glucose Monitoring in Diabetes: Source-Masked Multirater Comparative Evaluation.Journal of medical Internet research · 2026Article
- Wearable Devices and Machine Learning in Cardiovascular Monitoring: Current Evidence and Future Directions for Precision Medicine.Journal of personalized medicine · 2026Review
- Artificial Intelligence in Cardiovascular Medicine: A Giant Step in Personalized Medicine?Journal of personalized medicine · 2026Review
- AI-Enabled Sensor Technologies for Remote Arrhythmic Monitoring in High-Risk Cardiomyopathy Genotypes.Sensors (Basel, Switzerland) · 2026Review
- The Evolving Role of Artificial Intelligence and Machine Learning in the Wearable Electrocardiogram: A Primer on Wearable-Enabled Prediction of Cardiac Dysfunction.Bioengineering (Basel, Switzerland) · 2026Review
- Symptoms and causes of obstacles in AI-based telemonitoring: strategies for system development through a CRISP-DM lens.Frontiers in artificial intelligence · 2026Article
- Redefining cardiometabolic biomarkers in the big data era: toward a personalized medicine-centered reconstruction of risk prediction models.Frontiers in cardiovascular medicine · 2026Article
- Monitoring Atrial Fibrillation Using Wearable Digital Technologies: The Emerging Role of Smartwatches.Journal of clinical medicine · 2025Review
- Artificial intelligence-based remote monitoring for chronic heart failure: design and rationale of the SMART-CARE study.Frontiers in digital health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAI-integrated wearable devices (WDs) offer real-time cardiovascular disease (CVD) monitoring with the potential to improve early detection and patient-centred care. However, the breadth, quality, and clinical applicability of supporting evidence remain variable.
methodsA narrative review was conducted of peer-reviewed original studies, clinical trials, reviews, and regulatory documents published in English from January 2013 to June 2025. A structured Boolean search identified literature on AI-enabled WDs for cardiovascular monitoring. Selection criteria prioritised randomised trials, prospective observational studies, and real-world implementation reports with a clear regulatory context. Studies were narratively analysed for device classification, physiologic parameters measured, AI techniques, clinical validation outcomes, and evidence of patient engagement.
resultsEvidence demonstrates high diagnostic accuracy for arrhythmia detection and promising outcomes in heart failure monitoring, particularly with Food and Drug Administration or Conformité Européenne-approved devices. Nonetheless, most studies were small, short-term, and conducted in controlled settings, limiting generalisability. Key gaps include underrepresentation of diverse populations, lack of interoperability with electronic health records, limited AI explainability, and incomplete cost-effectiveness evaluation. Patient engagement was inconsistently addressed, with most reporting only basic usability or satisfaction measures rather than co-design or adherence optimisation strategies.
conclusionAI-integrated WDs show considerable promise in enhancing CVD detection and management but require large-scale pragmatic trials, standardised interoperability protocols, transparent AI model interpretability, and structured patient involvement. Addressing these gaps will be essential for equitable, scalable, and clinically integrated adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.